Gut microbiota and immune system in liver cancer: Promising therapeutic implication from development to treatment

doi:10.4251/wjgo.v13.i11.1616

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5904)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

399

WORD

117

HTML

3604

Figures (1-2)

308

Tables (1-2)

281

Sum=4709

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

444

Download

751

Sum=1195

Nov 15, 2021 (publication date) through Nov 24, 2024

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Oncol. Nov 15, 2021; 13(11): 1616-1631
Published online Nov 15, 2021. doi: 10.4251/wjgo.v13.i11.1616

Table 2 Different microbial composition in healthy and disease — hepatocellular carcinoma

Hepatitis B-related HCC[27]	NASH-related HCC[29]	Cirrhosis-related HCC[17]
↓: Faecalibacterium, Ruminococcus, Ruminoclostridium
↑: Escherichia, Shigella, Enterococcus	↑: Clostridium, Corynebacterium Bacillus, Desulfovibrio, Rhodococcus	↑: Epsilonproteobacteria, Actinobacteria, Clostridia, Fusobacterium, Oribacterium

↓/↑: Reduced or increased in patients compared to healthy volunteers; HCC: Hepatocellular carcinoma; NASH: Non-alcoholic steatohepatitis.

Citation: Bartolini I, Risaliti M, Tucci R, Muiesan P, Ringressi MN, Taddei A, Amedei A. Gut microbiota and immune system in liver cancer: Promising therapeutic implication from development to treatment. World J Gastrointest Oncol 2021; 13(11): 1616-1631
URL: https://www.wjgnet.com/1948-5204/full/v13/i11/1616.htm
DOI: https://dx.doi.org/10.4251/wjgo.v13.i11.1616